1 – 19 of 19
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females—Post-hoc analysis of a community-randomized clinical trial (II)
(
- Contribution to journal › Article
- 2011
-
Mark
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia
(
- Contribution to journal › Article
- 2010
-
Mark
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
(
- Contribution to journal › Article
-
Mark
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.
(
- Contribution to journal › Article
- 2009
-
Mark
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2008
-
Mark
Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection
(
- Contribution to journal › Article
-
Mark
Strengthening prevention programs to eliminate cervical cancer in the Nordic countries.
(
- Contribution to journal › Scientific review
-
Mark
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
(
- Contribution to journal › Article
- 2007
-
Mark
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
(
- Contribution to journal › Article
-
Mark
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
(
- Contribution to journal › Article
-
Mark
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
(
- Contribution to journal › Article
- 2006
-
Mark
Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries
(
- Contribution to journal › Article
- 2003
-
Mark
Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later.
(
- Contribution to journal › Article
-
Mark
Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer.
(
- Contribution to journal › Article
- 2002
-
Mark
The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review
(
- Contribution to journal › Article
-
Mark
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma.
(
- Contribution to journal › Article